Minerva Neurosciences, Inc. (NERV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 FY17: 0 FY18: 0 FY19: 0 FY20: 0 FY21: 0 FY22: 0 FY23: 0 FY24: 0 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-90M -60M -30M 0 30M 60M 90M FY16: -30.2M FY17: -41.2M FY18: -51.7M FY19: -75.9M FY20: 1.8M FY21: -45.4M FY22: -25.2M FY23: -23.1M FY24: -21.8M FY25: -15.1M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-300M -200M -100M 0 100M 200M 300M FY16: -31M FY17: -31.5M FY18: -50.2M FY19: -72.2M FY20: 1.9M FY21: -49.9M FY22: -32.1M FY23: -30M FY24: 1.4M FY25: -293.4M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-45M -30M -15M 0 15M 30M 45M FY16: -25.7M FY17: 3.1M FY18: -41.9M FY19: -43.4M FY20: -33.8M FY21: -24.6M FY22: -24.6M FY23: -14.8M FY24: -19.6M FY25: -13.5M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-45M -30M -15M 0 15M 30M 45M FY13: -2.2M FY14: -36M FY17: 3M FY22: -24.7M FY13 FY14 FY17 FY22

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY19: 39M FY20: 40.9M FY21: 5.3M FY22: 5.3M FY23: 6.5M FY24: 7.6M FY25: 8.5M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q3 '16: -1.06 Q4 '16: -0.99 Q1 '17: -1.00 Q2 '17: -1.09 Q3 '17: -1.13 Q4 '17: -0.84 Q1 '18: -0.86 Q2 '18: -0.91 Q3 '18: -0.94 Q4 '18: -1.29 Q1 '19: -1.38 Q2 '19: -1.38 Q3 '19: -1.43 Q4 '19: -1.86 Q1 '20: -1.76 Q2 '20: -0.71 Q3 '20: -0.54 Q4 '20: 0.05 Q1 '21: 0.15 Q2 '21: -0.83 Q3 '21: -2.36 Q4 '21: -6.17 Q1 '22: -7.79 Q2 '22: -9.17 Q3 '22: -8.74 Q4 '22: -6.01 Q1 '23: -5.49 Q2 '23: -4.98 Q3 '23: -4.72 Q4 '23: -4.66 Q1 '24: -4.48 Q2 '24: -4.45 Q3 '24: -0.45 Q4 '24: 0.19 Q1 '25: 0.82 Q2 '25: 1.48 Q3 '25: -1.85 Q4 '25: -34.67 Q1 '26: -37.03 Q2 '26: -36.74 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.